The combinatorial complexity of cancer precision medicine

Oncoscience

Volumn 1, Issue 7, 2014, Pages 504-509

  Klauschen, Frederick ^a   Andreeff, Michael ^b   Keilholz, Ulrich ^a   Dietel, Manfred ^a   Stenzinger, Albrecht ^c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Clinical Trial Design; Combination Therapies; Personalized Therapy; Precision Medicine; Systems Medicine

Indexed keywords

EID: 84921000983     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.66     Document Type: Article

References (34)

1. Jones PS and Jones D. New regulatory framework for cancer drug development. Drug Discov Today. 2012; 17(5-6): 227-231.
2. Joffe S and Miller FG. Equipoise: asking the right questions for clinical trial design. Nat Rev Clin Oncol. 2012; 9(4): 230-235.
3. Garraway LA. Genomics-driven oncology: framework for an emerging paradigm. J Clin Oncol. 2013; 31(15): 1806-1814.
4. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S and Sawyers CL. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14): 1031-1037.
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507-2516.
6. Arkenau HT, Kefford R and Long GV. Targeting BRAF for patients with melanoma. Br J Cancer. 2011; 104(3): 392-398.
7. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448(7153): 561-566.
8. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F, Wu YL, Thomas M, O'Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385-2394.
9. Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H and Ishikawa Y. RET, ROS1 and ALK fusions in lung cancer. Nat Med. 2012; 18(3): 378-381.
10. Bedard PL, Hansen AR, Ratain MJ and Siu LL. Tumour heterogeneity in the clinic. Nature. 2013; 501(7467): 355-364.
11. Baselga J. Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. Ann Oncol. 2013; 24(8): 1956-1957.
12. Willyard C. 'Basket studies' will hold intricate data for cancer drug approvals. Nat Med. 2013; 19(6): 655.
13. Sleijfer S, Bogaerts J and Siu LL. Designing transformative clinical trials in the cancer genome era. J Clin Oncol. 2013; 31(15): 1834-1841.
14. Heim D, Budczies J, Stenzinger A, Treue D, Hufnagl P, Denkert C, Dietel M and Klauschen F. Cancer beyond organ and tissue specificity: Next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. Int J Cancer. 2014.
15. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N and Sander C. Emerging landscape of oncogenic signatures across human cancers. Nat Genet. 2013; 45(10): 1127-1133.
16. Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, Leiserson MD, Miller CA, Welch JS, Walter MJ, Wendl MC, Ley TJ, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471): 333-339.
17. MDAndersonCancerCenter. BATTLE Program: Umbrella Protocol for Patients With NSCLC. http://clinicaltrialsgov/show/NCT00409968. 2013.
18. Kim ES, Herbst RS, Wistuba, II, Lee JJ, Blumenschein GR, Jr., Tsao A, Stewart DJ, Hicks ME, Erasmus J, Jr., Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, et al. The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov. 2011; 1(1): 44-53.
19. MDAndersonCancerCenter. BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study. http://clinicaltrialsgov/show/NCT01248247. 2014.
20. Berry DA. Adaptive clinical trials in oncology. Nat Rev Clin Oncol. 2012; 9(4): 199-207.
21. Rugo H, Olopade O, DeMichele A, van 't Veer L, Buxton M, Hylton N, Yee D, Jo Chien A, Wallace A, Lyandres J, Davis S, Sanil A, Berry D and Esserman L. Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY SABCS. 2013; Abstract S5-02.
22. Burrell RA, McGranahan N, Bartek J and Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature. 2013; 501(7467): 338-345.
23. Watson IR, Takahashi K, Futreal PA and Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013; 14(10): 703-718.
24. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA, Jr. and Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127): 1546-1558.
25. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489(7417): 519-525.
26. Wagle N, Berger MF, Davis MJ, Blumenstiel B, Defelice M, Pochanard P, Ducar M, Van Hummelen P, Macconaill LE, Hahn WC, Meyerson M, Gabriel SB and Garraway LA. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov. 2012; 2(1): 82-93.
27. Cook N, Jodrell DI and Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today. 2012; 17(5-6): 253-260.
28. Sharma MR and Schilsky RL. Role of randomized phase III trials in an era of effective targeted therapies. Nat Rev Clin Oncol. 2012; 9(4): 208-214.
29. Kirk R and Hutchinson L. Oncology trials-the elephant in the room. Nat Rev Clin Oncol. 2012; 9(4): 185-186.
30. Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 2012; 483(7387): 100-103.
31. Bahadoran P, Allegra M, Le DuffF, Long-Mira E, Hofman P, Giacchero D, Passeron T, Lacour JP and Ballotti R. Major clinical response to a BRAF inhibitor in a patient with a BRAF L597R-mutated melanoma. J Clin Oncol. 2013; 31(19): e324-326.
32. Swanton C, Andre F and Mardis E. Deciphering root causes of intrinsic BRAF inhibitor resistance in melanoma: ushering in a new genomics case reports feature for Annals of Oncology. Ann Oncol. 2014.
33. Turajlic S, Furney SJ, Stamp G, Rana S, Ricken G, Oduko Y, Saturno G, Springer C, Hayes A, Gore M, Larkin J and Marais R. Whole-genome sequencing reveals complex mechanisms of intrinsic resistance to BRAF inhibition. Ann Oncol. 2014.
34. Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ and Carpten JD. Whole-genome Sequencing of an Aggressive BRAF Wild-type Papillary Thyroid Cancer Identified EML4-ALK Translocation as a Therapeutic Target. World J Surg. 2014.